← Back to patent-cliff list

CAS 1430052-97-3

(2R,3S)-5-(Oxiran-2-ylmethoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol

Codes: Nadolol-007

Application context (from source-drug indications)

Diabetic macular oedemaNadololDiabetic retinopathyNadolol感染性角结膜炎NadololDry eye syndromeNadololHypertensionNadololHyperthyroidismNadolol

Source drugs (routes using this intermediate)

DrugTierExpiry
NadololTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

NadololOptimised routesteps: 6total yield: /
5,8-Dihydro-1-naphthol→alpha-Naphthyl acetate→cis-6,7-Dihydroxy-5,6,7,8-tetrahydronaphthalen-1-yl acetate→(6R,7S)-5,6,7,8-Tetrahydronaphthalene-1,6,7-triol→Sodium cis-6,7-dihydroxy-5,6,7,8-tetrahydronaphthalen-1-olate→(+/-)-2-(Chloromethyl)oxirane→(2R,3S)-5-(Oxiran-2-ylmethoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol→2-Methylpropan-2-amine

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.